Effects of ADMA upon gene expression: An insight into the pathophysiological significance of raised plasma ADMA

PLoS Medicine

Volumn 2, Issue 10, 2005, Pages 1031-1043

  Smith, Caroline L ^a   Anthony, Shelagh ^a   Hubank, Mike ^a   Leiper, James M ^a   Vallance, Patrick ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 2 INDUCIBLE KINASE; BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; MESSENGER RNA; N(G),N(G) DIMETHYLARGININE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 3; SMAD5 PROTEIN; UNCLASSIFIED DRUG; ARGININE; BMP2 PROTEIN, HUMAN; BMP2 PROTEIN, MOUSE; BMPR1A PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; PRMT3 PROTEIN, HUMAN; SMAD5 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

AMINO ACID BLOOD LEVEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; METHYLATION; MOUSE; MUTATION; NONHUMAN; NORTHERN BLOTTING; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; ATHEROSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CULTURE TECHNIQUE; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY;

ARGININE; ATHEROSCLEROSIS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEINS; CARDIOVASCULAR DISEASES; CELL CULTURE TECHNIQUES; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-ARGININE N-METHYLTRANSFERASES; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 27644497548     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020264     Document Type: Article

References (36)

1. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575.
2. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459.
3. Cooke JP (2004) Asymmetrical dimethylarginine: The Uber marker? Circulation 109: 1813-1818.
4. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, et al. (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62: 2425-2430.
5. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE (2001) Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37: 489-492.
6. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, et al. (1998) Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 98: 1842-1847.
7. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, et al. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117.
8. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, et al. (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128.
9. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, et al. (2003) Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop preeclampsia. Lancet 361: 1511-1517.
10. Tsikas D, Boger RH, Sandmann J, Bode-Boger SM, Frolich JC (2000) Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 478: 1-3.
11. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA (2003) Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 162: 533-546.
12. Seo J, Bakay M, Chen YW, Hilmer S, Shneiderman B, et al. (2004) Interactively optimizing signal-to-noise ratios in expression profiling: Project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics 20: 2534-2544.
13. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA (2002) Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303: 131-137.
14. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
15. Hosack DA, Glynn Dennis G, Sherman BT, Lane BC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4: R70.
16. Closs EI, Basha FZ, Habermeier A, Forstermann U (1997) Interference of Larginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1: 65-73.
17. Tang J, Gary JD, Clarke S, Herschman HR (1998). PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. J Biol Chem 273: 16935-16945.
18. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH (2001) Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl 78: S9-S13.
19. Zoccali C (2002) Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif 20: 469-472.
20. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, et al. (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287: 1420-1426.
21. MacAllister RJ, Whitley GS, Vallance P (1994) Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 45: 737-742.
22. Faruqi TR, Erzurum SC, Kaneko FT, DiCorleto PE (1997) Role of nitric oxide in poly(I-C)-induced endothelial cell expression of leukocyte adhesion molecules. Am J Physiol 273: (5 Pt 2): H2490-H2497.
23. Hemish J, Nakaya N, Mittal V, Enikolopov G (2003) Nitric oxide activates diverse signaling pathways to regulate gene expression. J Biol Chem 278: 42321-42329.
24. Cardounel AJ, Xia Y, Zweier JL (2005) Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric oxide synthase: Differences in the effects of monomethyl and dimethyl arginines in the presence and absence of tetrahydrobiopterin. J Biol Chem 280: 7540-7549.
25. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, et al. (2004) Asymmetric dimethylarginine causes arteriosclerotic lesions in endothelial nitric oxide synthase-deficient mice: Involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24: 1682-1688.
26. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS (2004) Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: Role in foam cell formation. Am J Physiol Heart Circ Physiol 287: H782-H790.
27. Cross JM, Donald AE, Kharbanda R, Deanfield JE, Woolfson RG, et al. (2001) Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int 60: 2318-2323.
28. Arrigoni FI, Vallance P, Haworth SG, Leiper JM (2003) Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 107: 1195-1201.
29. Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, et al. (2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108: 1493-1498.
30. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737-744.
31. Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, et al. (2004) Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol 24: 25-38.
32. Xiao ZS, Quarles LD, Chen QQ, Yu YH, Qu XP, et al. (2001) Effect of asymmetric dimethylarginine on osteoblastic differentiation. Kidney Int 60: 1699-1704.
33. Kearns AE, Donohue MM, Sanyal B, Demay MB (2001) Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro. J Biol Chem. 276: 42213-42218.
34. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, et al. (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87: 99-105.
35. Bachand F, Silver PA (2004) PRMT3 is a ribosomal protein methyltransferase that affects the cellular levels of ribosomal subunits. EMBO J 23: 2641-2650.
36. Casellas P, Jeanteur P (1978) Protein methylation in animal cells. II. Inhibition of S-adenosyl-L-methionine:protein(arginine) N-methyltransferase by analogs of S-adenosyl-L-homocysteine. Biochim Biophys Acta 519: 255-268.